Tuesday, February 7, 2023


Biotechnology News Magazine


Deciphex Completes Validation Activities Enabling Veterinary Consultant Pathologists to Perform CLP Peer Review Digitally Using Patholytix

GLP and non-GLP studies can now be digitally peer reviewed by consultant pathologists for CROs and Pharma companies leading to faster study review and reduced backlogs with Drug candidates brought to clinical trials sooner advises Deciphex.

TAU Systems Signs an Agreement with The University of Texas at Austin

TAU Systems notes the collaboration utilizes The University of Texas' Tabletop Terawatt Laboratory laser system to expedite breakthroughs in disease prevention and cures, as well as semiconductor chips and more.

Sequana Medical Announces Grant of Additional DSR® Patent in the United States

Ian Crosbie, Chief Executive Officer of Sequana Medical, commented: “The granting of this important patent further strengthens the intellectual property protection of our DSR program and is important given the strong results from our SAHARA study we reported at the end of last year. This Phase 2a study using our first-generation DSR product showed the potential of DSR as disease-modifying heart failure drug therapy with long-lasting clinical benefits. We are now preparing for the IND filing of our second-generation DSR product, and are planning to starting MOJAVE, our US Phase 1/2a randomized controlled study in patients with congestive heart failure.”

Orbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeutics

The agreement covers activities ranging from hit ID to development of cell-based assays, with an option for Endevica to further develop the peptide hits resulting from the screening activities.

SK bioscience Introduces New Partnership Model to Establish Regional Vaccine Hubs

Mr. Ahn said, "SK bioscience can transplant vaccine manufacturing facilities, technologies, and products to any countries in need based on the accumulated experiences in R&D and manufacturing we have been building. A bilateral partnership can be established if the country in need is willing to provide funds, human resources, and overall environments with collaboration of global initiatives."

Genmab Announces Net Sales of DARZALEX ® (daratumumab) for 2022

Net sales of DARZALEX ® in 2022 totaled USD 7,977 million. Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen).